HLTF and its implication in cancer progression

[en] The helicase-like transcription factor (HLTF) belongs to the SWI/SNF family of chromatin-remodeling factors. Several SWI/SNF genes are disrupted in cancer, suggesting their possible role as tumor suppressors. Similarly, the HLTF gene was found to be inactivated by hypermethylation in a significant number of colon, gastric and uterine tumors, indicating that HLTF silencing may confer a growth advantage and that HLTF could be considered as a tumor suppressor gene. However, 20-fold HLTF overexpression was detected in various transformed cell lines, suggesting that HLTF could be associated with neoplastic transformation and act more like an oncogene. Moreover, HLTF activation was recently linked to the initial steps of carcinogenesis in an experimental model of estrogen-induced kidney tumors. Those apparently contradictory observations suggest that HLTF might play various roles in cancer. In this review, we will try to reconcile all these data in order to specify the role of HLTF in cancer progression

Disciplines :

Immunology & infectious disease
Oncology
Biochemistry, biophysics & molecular biology
Biotechnology

Author, co-author :

Debauve, Gaël

Capouillez, Aurélie

Belayew, Alexandra ; Université de Mons > Faculté de Médecine et de Pharmacie > Biochimie métabolique et moléculaire

Saussez, Sven ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale

Language :

English

Title :

HLTF and its implication in cancer progression

Publication date :

01 January 2008

Journal title :

Cellular and Molecular Life Sciences

ISSN :

1420-682X

Publisher :

Birkhauser Verlag, Switzerland

Volume :

Issue :

Pages :

591-604

Peer reviewed :

Peer Reviewed verified by ORBi

Research unit :

M112 - Anatomie humaine et Oncologie expérimentale
M122 - Biochimie métabolique et moléculaire

Available on ORBi UMONS :

since 10 July 2010

Statistics

Number of views

2 (0 by UMONS)

Number of downloads

12 (0 by UMONS)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kornberg, R. D. and Lorch, Y. (1999) Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98, 285-294.
Owen-Hughes, T. (2003) Colworth Memorial Lecture: Pathways for remodelling chromatin. Biochem. Soc. Trans. 31, 893-905.
Mohrmann, L. and Verrijzer, C. P. (2005) Composition and functional specificity of SWI2/SNF2 class chromatin remodeling complexes. Biochim. Biophys. Acta 1681, 59-73.
Li, B., Carey, M. and Workman, J. L. (2007) The role of chromatin during transcription. Cell, 128, 707-719.
5Lorch, Y., Zhang, M. and Kornberg, R. D. (1999) Histone octamer transfer by a chromatin-remodeling complex. Cell 96, 389-392.
Roberts, C. W. and Orkin, S. H. (2004) The SWI/SNF complex - chromatin and cancer. Nat. Rev. Cancer 4, 133-142.
Biegel, J. A., Zhou, J. Y., Rorke, L. B., Stenstrom, C., Wainwright, L. M. and Fogelgren, B. (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74-79.
Versteege, I., Sevenet, N., Lange, J., Rousseau-Merck, M. F., Ambros, P., Handgretinger, R., Aurias, A. and Delattre, O. (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206.
Roberts, C. W., Leroux, M. M., Fleming, M. D. and Orkin, S. H. (2002) Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2, 415-425.
Bai, A. H., Tong, J. H., To, K. F., Chan, M. W., Man, E. P., Lo, K. W., Lee, J. F., Sung, J. J. and Leung, W. K. (2004) Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int. J. Cancer 112, 846-853.
Brandes, J. C., van Engeland, M., Wouters, K. A., Weijenberg, M. P. and Herman, J. G. (2005) CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26, 1152-1156.
Hibi, K., Nakayama, H., Kanyama, Y., Kodera, Y., Ito, K., Akiyama, S. and Nakao, A. (2003) Methylation pattern of HLTF. gene in digestive tract cancers. Int. J. Cancer 104, 433-436.
Hibi, K., Kodera, Y., Ito, K., Akiyama, S. and Nakao, A. (2005) Aberrant methylation of HLTF, SOCS-1 and CDH13 genes is shown in colorectal cancers without lymph node metastasis. Dis. Colon Rectum 48, 1282-1286.
Hibi, K. and Nakao, A. (2006) Highly-methylated colorectal cancers show poorly-differentiated phenotype. Anticancer Res. 26, 4263-4266.
Hibi, K. and Nakao, A. (2006) Lymph node metastasis is infrequent in patients with highly-methylated colorectal cancer. Anticancer Res. 26, 55-58.
Kim, Y. H., Petko, Z., Dzieciatkowski, S., Lin, L., Ghiassi, M., Stain, S., Chapman, W. C., Washington, M. K., Willis, J., Markowitz, S. D. and Grady, W. M. (2006) CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosom. Cancer 45, 781-789.
Leung, W. K., To, K. F., Man, E. P., Chan, M. W., Bai, A. H., Hui, A. J., Chan, F. K., Lee, J. F. and Sung, J. J. (2004) Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem. 50, 2179-2182.
Leung, W. K., To, K. F., Man, E. P., Chan, M. W., Bai, A. H., Hui, A. J., Chan, F. K. and Sung, J. J. (2005) Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 100, 2274-2279.
Leung, W. K., To, K. F., Man, E. P., Chan, M. W., Hui, A. J., Ng, S. S., Lau, J. Y. and Sung, J. J. (2007) Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am. J. Gastroenterol. 102, 1070-1076.
Moinova, H. R., Chen, W. D., Shen, L., Smiraglia, D., Olechnowicz, J., Ravi, L., Kasturi, L., Myeroff, L., Plass, C., Parsons, R., Minna, J., Willson, J. K., Green, S. B., Issa, J. P. and Markowitz, S. D. (2002) HLTF gene silencing in human colon cancer. Proc. Natl. Acad. Sci. USA, 99, 4562-4567.
Kang, M. Y., Lee, B. B., Kim, Y. H., Chang, D. K., Kyu, P. S., Chun, H. K., Song, S. Y., Park, J. and Kim, D. H. (2007) Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer. Int. J. Cancer 121, 2192-2197.
Hamai, Y., Oue, N., Mitani, Y., Nakayama, H., Ito, R., Matsusaki, K., Yoshida, K., Toge, T. and Yasui, W. (2003) DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci. 94, 692-698.
Kim, J. J., Chung, S. W., Kim, J. H., Kim, J. W., Oh, J. S., Kim, S., Song, S. Y., Park, J. and Kim, D. H. (2006) Promoter methylation of helicase-like transcription factor is associated with the early stages of gastric cancer with family history. Ann. Oncol. 17, 657-662.
Leung, W. K., Yu, J., Bai, A. H., Chan, M. W., Chan, K. K., To, K. F., Chan, F. K., Ng, E. K., Chung, S. C. and Sung, J. J. (2003) Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer. Mol. Carcinog. 37, 91-97.
Oue, N., Mitani, Y., Motoshita, J., Matsumura, S., Yoshida, K., Kuniyasu, H., Nakayama, H. and Yasui, W. (2006) Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 106, 1250-1259.
Fukuoka, T., Hibi, K. and Nakao, A. (2006) Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma. Anticancer Res. 26, 3333-3335.
Kang, S., Kim, J. W., Kang, G. H., Lee, S., Park, N. H., Song, Y. S., Park, S. Y., Kang, S. B. and Lee, H. P. (2006) Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int. J. Cancer, 118, 2168-2171.
Jo, H., Kang, S., Kim, J. W., Kang, G. H., Park, N. H., Song, Y. S., Park, S. Y., Kang, S. B. and Lee, H. P. (2007) Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer. J. Obstet. Gynaecol. Res. 33, 236-241.
Debauve, G., Nonclercq, D., Ribaucour, F., Wiedig, M., Gerbaux, C., Leo, O., Laurent, G., Journe, F., Belayew, A. and Toubeau, G. (2006) Early expression of the helicase-like transcription factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis. Mol. Cancer 5, 23.
Sheridan, P. L., Schorpp, M., Voz, M. L. and Jones, K. A. (1995) Cloning of an SNF2/SWI2-related protein that binds specifically to the SPH motifs of the SV40 enhancer and to the HIV-1 promoter. J. Biol. Chem. 270, 4575-4587.
Ding, H., Descheemaeker, K., Marynen, P., Nelles, L., Carvalho, T., Carmo-Fonseca, M., Collen, D. and Belayew, A. (1996) Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene. DNA Cell Biol. 15, 429-442.
Zhang, Q., Ekhterae, D. and Kim, K. H. (1997) Molecular cloning and characterization of P113, a mouse SNF2/SWI2-related transcription factor. Gene 202, 31-37.
Hayward-Lester, A., Hewetson, A., Beale, E. G., Oefner, P. J., Doris, P. A. and Chilton, B. S. (1996) Cloning, characterization, and steroid-dependent posttranscriptional processing of RUSH-1 alpha and beta, two uteroglobin promoter-binding proteins. Mol. Endocrinol. 10, 1335-1349.
Gong, X., Kaushal, S., Ceccarelli, E., Bogdanova, N., Neville, C., Nguyen, T., Clark, H., Khatib, Z. A., Valentine, M., Look, A. T. and Rosenthal, N. (1997) Developmental regulation of Zbu1, a DNA-binding member of the SWI2/SNF2 family. Dev. Biol. 183, 166-182.
Mahajan, M. C. and Weissman, S. M. (2002) DNA-dependent adenosine triphosphatase (helicaselike transcription factor) activates beta-globin transcription in K562 cells. Blood 99, 348-356.
Ding, H., Benotmane, A. M., Suske, G., Collen, D. and Belayew, A. (1999) Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene. J. Biol. Chem. 274, 19573-19580.
Hewetson, A. and Chilton, B. S. (2003) An Sp1-NF-Y/progesterone receptor DNA binding-dependent mechanism regulates progesterone-induced transcriptional activation of the rabbit RUSH/SMARCA3 gene. J. Biol. Chem. 278, 40177-40185.
Hewetson, A., Hendrix, E. C., Mansharamani, M., Lee, V. H. and Chilton, B. S. (2002) Identification of the RUSH consensus-binding site by cyclic amplification and selection of targets: demonstration that RUSH mediates the ability of prolactin to augment progesterone-dependent gene expression. Mol. Endocrinol. 16, 2101-2112.
Bole-Feysot, C., Goffin, V., Edery, M., Binart, N. and Kelly, P. A. (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 19, 225-268.
Hewetson, A., Moore, S. L. and Chilton, B. S. (2004) Prolactin signals through RUSH/SMARCA3 in the absence of a physical association with Stat5a. Biol. Reprod. 71, 1907-1912.
Lin, Y., Sheridan, P. L., Jones, K. A. and Evans, G. A. (1995) The HIP116 SNF2/SW12-related transcription factor gene (SNF2L3) is located on human chromosome 3q25.1-q26.1. Genomics 27, 381-382.
Iyer, L. M., Babu, M. M. and Aravind, L. (2006) The HIRAN domain and recruitment of chromatin remodeling and repair activities to damaged DNA. Cell Cycle 5, 775-782.
Eisen, J. A., Sweder, K. S. and Hanawalt, P. C. (1995) Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res., 23, 2715-2723.
Linder, B., Cabot, R. A., Schwickert, T. and Rupp, R. A. (2004) The SNF2 domain protein family in higher vertebrates displays dynamic expression patterns in Xenopus laevis embryos. Gene 326, 59-66.
Flaus, A., Martin, D. M., Barton, G. J. and Owen-Hughes, T. (2006) Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res. 34, 2887-2905.
Chen, S., Davies, A. A., Sagan, D. and Ulrich, H. D. (2005) The RING finger ATPase Rad5p of Saccharomyces cerevisiae contributes to DNA double-strand break repair in a ubiquitinin-dependent manner. Nucleic Acids Res. 33, 5878-5886.
Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. and Jentsch, S. (2002) RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-141.
Ramsey, K. L., Smith, J. J., Dasgupta, A., Maqani, N., Grant, P. and Auble, D. T. (2004) The NEF4 complex regulates Rad4 levels and utilizes Snf2/Swi2-related ATPase activity for nucleotide excision repair. Mol. Cell Biol. 24, 6362-6378.
Yu, S., Owen-Hughes, T., Friedberg, E. C., Waters, R. and Reed, S. H. (2004) The yeast Rad7/Rad16/Abf1 complex generates superhelical torsion in DNA that is required for nucleotide excision repair. DNA Repair (Amst.) 3, 277-287.
Morris, J. R., Pangon, L., Boutell, C., Katagiri, T., Keep, N. H. and Solomon, E. (2006) Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum. Mol. Genet. 15, 599-606.
Ulrich HD (2003) Protein-protein interactions within an E2-RING finger complex: implications for ubiquitin-dependent DNA damage repair. J. Biol. Chem. 278, 7051-7058.
Xia, Y., Pao, G. M., Chen, H. W., Verma, I. M. and Hunter, T. (2003) Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Biol. Chem. 278, 5255-5263.
Devine, J. H., Hewetson, A., Lee, V. H. and Chilton, B. S. (1999) After chromatin is SWItched-on can it be RUSHed? Mol. Cell Endocrinol. 151, 49-56.
Mansharamani, M., Hewetson, A. and Chilton, B. S. (2001) Cloning and characterization of an atypical type IV P-type ATPase that binds to the RING motif of RUSH transcription factors. J. Biol. Chem. 276, 3641-3649.
Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
Chuang, J. C. and Jones, P. A. (2007) Epigenetics and Micro-RNAs. Pediatr. Res. 61. 24R-29R
Klose, R. J. and Bird, A. P. (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31, 89-97.
Esteller, M. (2005) Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45, 629-656.
Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298.
Bird, A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev., 16, 6-21.
Maley, C. C., Galipeau, P. C., Li, X., Sanchez, C. A., Paulson, T. G. and Reid, B. J. (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64, 3414-3427.
Toyota, M. and Issa, J. P. (2000) The role of DNA hypermethylation in human neoplasia. Electrophoresis 21, 329-333.
Issa, J. P., Shen, L. and Toyota, M. (2005) CIMP, at last. Gastroenterology 129, 1121-1124.
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K. and Slattery, M. L. (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65, 6063-6069.
Bariol, C., Suter, C., Cheong, K., Ku, S. L., Meagher, A., Hawkins, N. and Ward, R. (2003) The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am. J. Pathol. 162, 1361-1371.
Rashid, A., Shen, L., Morris, J. S., Issa, J. P. and Hamilton, S. R. (2001) CpG island methylation in colorectal adenomas. Am. J. Pathol. 159, 1129-1135.
Jen, J., Wu, L. and Sidransky, D. (2000) An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann. N. Y. Acad. Sci. 906, 8-12.
Ahlquist, D. A., Skoletsky, J. E., Boynton, K. A., Harrington, J. J., Mahoney, D. W., Pierceall, W. E., Thibodeau, S. N. and Shuber, A. P. (2000) Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219-1227.
Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. and Baylin, S. B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826.
Widschwendter, M. and Menon, U. (2006) Circulating methylated DNA: a new generation of tumor markers. Clin. Cancer Res. 12, 7205-7208.
Wallner, M., Herbst, A., Behrens, A., Crispin, A., Stieber, P., Goke, B., Lamerz, R. and Kolligs, F. T. (2006) Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 12, 7347-7352.
Lenhard, K., Bommer, G. T., Asutay, S., Schauer, R., Brabletz, T., Goke, B., Lamerz, R. and Kolligs, F. T. (2005) Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol. 3, 142-149.
Leung, W. K., To, K. F., Man, E. P., Chan, M. W., Bai, A. H., Hui, A. J., Chan, F. K., Lee, J. F. and Sung, J. J. (2004) Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem. 50, 2179-2182.
Muller, H. M., Oberwalder, M., Fiegl, H., Morandell, M., Goebel, G., Zitt, M., Muhlthaler, M., Ofner, D., Margreiter, R. and Widschwendter, M. (2004) Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363, 1283-1285.
Petko, Z., Ghiassi, M., Shuber, A., Gorham, J., Smalley, W., Washington, M. K., Schultenover, S., Gautam, S., Markowitz, S. D. and Grady, W. M. (2005) Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 11, 1203-1209.
Fuchs, C. S. and Mayer, R. J. (1995) Gastric carcinoma. N. Engl. J. Med. 333, 32-41.
Kang, G. H., Lee, S., Kim, J. S. and Jung, H. Y. (2003) Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab. Invest. 83, 635-641.
Oue, N., Shigeishi, H., Kuniyasu, H., Yokozaki, H., Kuraoka, K., Ito, R. and Yasui, W. (2001) Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int. J. Cancer 93, 805-809.
Kondo, T., Oue, N., Yoshida, K., Mitani, Y., Naka, K., Nakayama, H. and Yasui, W. (2004) Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res. 64, 523-529.
Brock, M. V., Gou, M., Akiyama, Y., Muller, A., Wu, T. T., Montgomery, E., Deasel, M., Germonpre, P., Rubinson, L., Heitmiller, R. F., Yang, S. C., Forastiere, A. A., Baylin, S. B. and Herman, J. G. (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin. Cancer Res. 9, 2912-2919.
Oshimo, Y., Oue, N., Mitani, Y., Nakayama, H., Kitadai, Y., Yoshida, K., Chayama, K. and Yasui, W. (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int. J. Cancer 110, 212-218.
Oue, N., Oshimo, Y., Nakayama, H., Ito, R., Yoshida, K., Matsusaki, K. and Yasui, W. (2003) DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci. 94, 901-905.
Toyota, M., Ahuja, N., Suzuki, H., Itoh, F., Ohe-Toyota, M., Imai, K., Baylin, S. B. and Issa, J. P. (1999) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59, 5438-5442.
Hollstein, M. C., Metcalf, R. A., Welsh, J. A., Montesano, R. and Harris, C. C. (1990) Frequent mutation of the p53 gene in human esophageal cancer. Proc. Natl. Acad. Sci. USA 87, 9958-9961.
Jiang, W., Zhang, Y. J., Kahn, S. M., Hollstein, M. C., Santella, R. M., Lu, S. H., Harris, C. C., Montesano, R. and Weinstein, I. B. (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA 90, 9026-9030.
Tsuda, T., Nakatani, H., Tahara, E., Sakamoto, H., Terada, M. and Sugimura, T. (1989) HST1 and INT2 gene coamplification in a squamous cell carcinoma of the gallbladder. Jpn. J. Clin. Oncol. 19, 26-29.
Zhou, X., Tarmin, L., Yin, J., Jiang, H. Y., Suzuki, H., Rhyu, M. G., Abraham, J. M. and Meltzer, S. J. (1994) The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9, 3737-3741.
Hibi, K., Taguchi, M., Nakayama, H., Takase, T., Kasai, Y., Ito, K., Akiyama, S. and Nakao, A. (2001) Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 7, 3135-3138.
Cullen, A. P., Reid, R., Campion, M. and Lorincz, A. T. (1991) Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65, 606-612.
Dong, S. M., Kim, H. S., Rha, S. H. and Sidransky, D. (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7, 1982-1986.
Olson, D., Pollanen, J., Hoyer-Hansen, G., Ronne, E., Sakaguchi, K., Wun, T. C., Appella, E., Dano, K. and Blasi, F. (1992) Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J. Biol. Chem. 267, 9129-9133.
Steinmetzer, T. (2003) Synthetic urokinase inhibitors as potential antitumor drugs. IDrugs. 6, 138-146.
Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Hofler, H., Janicke, F. and Graeff, H. (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78, 285-296.
Fen, L. C., Kandel, C., Baliko, F., Nadesan, P., Brunner, N. and Alman, B. A. (2005) Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor). Oncogene 24, 1615-1624.
Sakakibara, T., Hibi, K., Koike, M., Fujiwara, M., Kodera, Y., Ito, K. and Nakao, A. (2005) Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br. J. Cancer 93, 799-803.
Sakakibara, T., Hibi, K., Koike, M., Fujiwara, M., Kodera, Y., Ito, K. and Nakao, A. (2006) Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci. 97, 395-399.
Hazelbag, S., Kenter, G. G., Gorter, A. and Fleuren, G. J. (2004) Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int. J. Cancer 112, 1020-1028.
Saurin, A. J., Borden, K. L., Boddy, M. N. and Freemont, P. S. (1996) Does this have a familiar RING? Trends Biochem. Sci. 21, 208-214.
Li, W., Tu, D., Brunger, A. T. and Ye, Y. (2007) A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. Nature 446, 333-337.
Ding, H., Beckers, M. C., Plaisance, S., Marynen, P., Collen, D. and Belayew, A. (1998) Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements. Hum. Mol. Genet. 7, 1681-1694.
Dixit, M., Ansseau, E., Tassin, A., Winokur, S., Shi, R., Qian, H., Sauvage, S., Mattéotti, C., Van Acker, A., Leo, O., Figlewicz, D., Barro, M., Laoudj-Chenivesse, D., Belayew, A., Coppée, F. and Chen, Y. W. (2007) DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc. Natl. Acad. Sci. U.S.A, 104, 18157-18162.
Szymanska, K. and Hainaut, P. (2003) TP53 and mutations in human cancer. Acta Biochim. Pol. 50, 231-238.
Androphy, E., Doshi, N. and Belayew, A. (2003) Diagnosis and treatment of cancer. New England Medical Center and University of Mons-Hainaut. [7,183,051]. Boston, MA; Mons, BE. 27-6-2002.